CarcinomaNCT01614002
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
An observational study of Carcinoma, run by Onkovis GmbH at 23 sites in Germany.
Trial summary
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Carcinoma
- How many people
- 371 participants
- Where
- 23 sitesGermany
- Study dates
- May 2012to Mar 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients treated in practices, clinics, hospitals
Who may be able to join
- Indication for Docetaxel according to the SmPC and treating physician
Who cannot join
- according to the Docetaxel SmPC
Trial locations and contacts
23 sites in 1 country.
23 sites in 1 country
Germany23 sites
Practice
Berlin, 13156
Practice
Brandenburg, 14770
Practice
Chemnitz, 09117
Practice
Cottbus, 03055
Practice
Dresden, 01307
Practice
Elstra, 01920
Practice
Freital, 01705
Practice
Fürstenwalde, 15517
Practice
Halle, 06132
Practice
Köthen, 06366
Practice
Kronach, 96317
Hospital
Leipzig, 04277
Practice
Leipzig, 04277
Practice
Magdeburg, 39104
Practice
Meiningen, 98617
Practice
Mühlhausen, 99974
Practice
Parchim, 19370
Practice
Plauen, 08525
Practice
Scheibenberg, 09481
Clinic
Torgau, 04860
Practice
Werdau, 08412
Practice
Zittau, 02763
Practice
Zwickau, 08060
About this study
Official title: Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region.
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
onkovis aims an economical utilization of the chemotherapeutics.The provision with adapted packaging sizes as to decrease the excess quantity to be discarded follows also this objective.
Secondary objectives are the evaluation of the safety and tolerability of Doce onkovis. To this purpose data regarding co medications and adverse events are also collected.
- Conditions
- Carcinoma
- Keywords
- carcinoma, breast cancer, non-small cell lung cancer, prostata cancer, adenocarcinoma of the stomach, squamous cell carcinoma of the head and neck region, ambulant chemotherapy, treatment cycles, Docetaxel, Doce onkovis, Quantity of Docetaxel, Packaging Sizes
- Medical subject headings
- Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| carcinoma, Doce onkovis (Docetaxel) | treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region. |
What is being measured
The primary outcome is the main question the study is designed to answer.
the quantity of Doce onkovis needed pro treatment cycle
Determine the quantity of Doce onkovis needed pro treatment cycle
Measured: the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles).
Secondary outcomes (1)
adverse events during and after treatment
The number and kind of adverse events during and after the intra-venous application of Docetaxel will be assessed and documented.
Measured: up to 24 weeks (8 cycles)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2012 (estimated)
- Study startMay 2012
- Primary completionMar 2015
- Study completionMar 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 371 participants (actual)
Sponsor and investigators
- Lead sponsor
- Onkovis GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- AKP Freiburg GmbH
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01614002
- Sponsor's protocol ID
- ONKODOC 01
- Status last verified
- Jun 2015
- First submitted
- 1 Jun 2012
- Last updated
- 4 Jun 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region.
- ClinicalTrials.gov ID
- NCT01614002
- Acronym / sponsor ID
- ONKODOC 01
- Conditions
- Carcinoma
- Keywords
- carcinoma, breast cancer, non-small cell lung cancer, prostata cancer, adenocarcinoma of the stomach, squamous cell carcinoma of the head and neck region, ambulant chemotherapy, treatment cycles
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 371 participants (actual)
- Lead sponsor
- Onkovis GmbHIndustry (pharma, biotech, devices)
- Collaborators
- AKP Freiburg GmbH
- Study start
- May 2012
- Primary completion
- Mar 2015 (actual)
- Study completion
- Mar 2015 (actual)
- First posted
- 7 Jun 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
onkovis aims an economical utilization of the chemotherapeutics.The provision with adapted packaging sizes as to decrease the excess quantity to be discarded follows also this objective.
Secondary objectives are the evaluation of the safety and tolerability of Doce onkovis. To this purpose data regarding co medications and adverse events are also collected.
Study design
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| carcinoma, Doce onkovis (Docetaxel) | – | –treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients treated in practices, clinics, hospitals
Key inclusion criteria (1 listed)
- Indication for Docetaxel according to the SmPC and treating physician
Key exclusion criteria (1 listed)
- according to the Docetaxel SmPC
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the quantity of Doce onkovis needed pro treatment cycle
Time frame: the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles).
Determine the quantity of Doce onkovis needed pro treatment cycle
1 secondary outcome
adverse events during and after treatment
Time frame: up to 24 weeks (8 cycles)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2015.
Related trials for Carcinoma
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
RecruitingPhase 2
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Esophageal Squamous Cell Carcinoma, Immunotherapy
Not yet recruitingPhase 3
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (Icc)
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
Active, not recruitingPhase 2
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Thymoma, Thymic Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
23 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carcinoma, run by Onkovis GmbH at 23 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 23 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the quantity of Doce onkovis needed pro treatment cycle (time frame: the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2015.